Literature DB >> 17242144

Pharmacokinetic/pharmacodynamic factors influencing emergence of resistance to linezolid in an in vitro model.

Lauren M Boak1, Jian Li, Craig R Rayner, Roger L Nation.   

Abstract

Emerging resistance threatens the usefulness of linezolid for the treatment of severe infections caused by multidrug-resistant gram-positive bacteria. Optimal pharmacokinetic (PK)/pharmacodynamic (PD) indices have been described for the antimicrobial efficacy of linezolid (area under the concentration-time curve over 24 h at steady state divided by the MIC, >100; the cumulative percentage of a 24-h period that the drug concentration exceeds the MIC under steady-state PK conditions, >85). The aim of this study was to investigate the influence of these PK/PD indices on the development of resistance to linezolid by using an in vitro PK/PD model. Four dosage regimens were simulated over 72 h (two intermittent bolus regimens of 600 mg every 12 h [q12h] and 120 mg q12h and two continuous-infusion regimens of 120 mg/24 h and 30 mg/24 h) against four reference strains: methicillin-resistant Staphylococcus aureus (MRSA), heteroresistant vancomycin-intermediate S. aureus (hVISA), vancomycin-intermediate S. aureus (VISA), and vancomycin-resistant Enterococcus faecium (VRE). Linezolid concentrations were measured by high-performance liquid chromatography. Changes in susceptibility were characterized by pre- and posttreatment MIC measurements and population analysis profiles (PAPs). The linezolid concentrations that were achieved closely matched those that were targeted. The simulation with 600 mg q12h provided a >3-log10 reduction in the number of CFU/ml for all four strains, as did the 120-mg-q12h regimen for hVISA and VISA and the 30-mg/24-h continuous infusion for VRE and VISA. After 72 h of exposure to the 120-mg/24-h continuous-infusion simulation, the area under the PAP curve for all strains increased substantially (40 to 178%); increases in the MICs for the MRSA and hVISA strains were observed. The results demonstrate that PK/PD considerations are important in optimizing both antibacterial activity and the development of resistance to linezolid. The potential for resistance development appears to be higher when a constant concentration is maintained in the vicinity of the MIC of the bacteria.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17242144      PMCID: PMC1855482          DOI: 10.1128/AAC.01194-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  27 in total

1.  Susceptibility testing with linezolid by different methods, in relation to published 'general breakpoints'.

Authors:  D M Livermore; S Mushtaq; M Warner
Journal:  J Antimicrob Chemother       Date:  2001-09       Impact factor: 5.790

2.  Infections due to vancomycin-resistant Enterococcus faecium resistant to linezolid.

Authors:  R D Gonzales; P C Schreckenberger; M B Graham; S Kelkar; K DenBesten; J P Quinn
Journal:  Lancet       Date:  2001-04-14       Impact factor: 79.321

3.  Linezolid-resistant Staphylococcus aureus in two pediatric patients receiving low-dose linezolid therapy.

Authors:  Susanne M Roberts; Alexandra F Freeman; Susan M Harrington; Steven M Holland; Patrick R Murray; Adrian M Zelazny
Journal:  Pediatr Infect Dis J       Date:  2006-06       Impact factor: 2.129

Review 4.  Linezolid.

Authors:  D Clemett; A Markham
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

5.  Linezolid resistance in a clinical isolate of Staphylococcus aureus.

Authors:  S Tsiodras; H S Gold; G Sakoulas; G M Eliopoulos; C Wennersten; L Venkataraman; R C Moellering; M J Ferraro
Journal:  Lancet       Date:  2001-07-21       Impact factor: 79.321

6.  Efficacy of linezolid in a staphylococcal endocarditis rabbit model.

Authors:  M P Oramas-Shirey; L V Buchanan; C L Dileto-Fang; C F Dailey; C W Ford; D H Batts; J K Gibson
Journal:  J Antimicrob Chemother       Date:  2001-03       Impact factor: 5.790

7.  Efficacy of linezolid in treatment of experimental endocarditis caused by methicillin-resistant Staphylococcus aureus.

Authors:  C F Dailey; C L Dileto-Fang; L V Buchanan; M P Oramas-Shirey; D H Batts; C W Ford; J K Gibson
Journal:  Antimicrob Agents Chemother       Date:  2001-08       Impact factor: 5.191

8.  Linezolid-resistant Enterococcus faecium isolated from a patient without prior exposure to an oxazolidinone: report from the SENTRY Antimicrobial Surveillance Program.

Authors:  Ronald N Jones; Phyllis Della-Latta; Lillian V Lee; Douglas J Biedenbach
Journal:  Diagn Microbiol Infect Dis       Date:  2002-02       Impact factor: 2.803

9.  Linezolid (PNU-100766) versus vancomycin in the treatment of hospitalized patients with nosocomial pneumonia: a randomized, double-blind, multicenter study.

Authors:  E Rubinstein; S Cammarata; T Oliphant; R Wunderink
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

10.  In vitro activities of quinupristin-dalfopristin and cefepime, alone and in combination with various antimicrobials, against multidrug-resistant staphylococci and enterococci in an in vitro pharmacodynamic model.

Authors:  George P Allen; Raymond Cha; Michael J Rybak
Journal:  Antimicrob Agents Chemother       Date:  2002-08       Impact factor: 5.191

View more
  21 in total

Review 1.  Pharmacokinetic and pharmacodynamic parameters of antimicrobials: potential for providing dosing regimens that are less vulnerable to resistance.

Authors:  Chiara Adembri; Andrea Novelli
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

2.  The emergence of linezolid resistance among Enterococci in intestinal microbiota of treated patients is unrelated to individual pharmacokinetic characteristics.

Authors:  N Bourgeois-Nicolaos; T T Nguyen; G Defrance; L Massias; L Alavoine; A Lefort; V Noel; E Senneville; F Doucet-Populaire; F Mentré; A Andremont; X Duval
Journal:  Antimicrob Agents Chemother       Date:  2014-02-24       Impact factor: 5.191

3.  In vitro simulation of in vivo pharmacokinetic model with intravenous administration via flow rate modulation.

Authors:  Yuan-Cheng Chen; Wang Liang; Jia-Li Hu; Gao-Li He; Xiao-Jie Wu; Xiao-Fang Liu; Jing Zhang; Xue-Qian Hu
Journal:  J Pharmacokinet Pharmacodyn       Date:  2014-10-30       Impact factor: 2.745

Review 4.  Pharmacological issues of linezolid: an updated critical review.

Authors:  Antonello Di Paolo; Paolo Malacarne; Emanuele Guidotti; Romano Danesi; Mario Del Tacca
Journal:  Clin Pharmacokinet       Date:  2010-07       Impact factor: 6.447

Review 5.  Individualising Therapy to Minimize Bacterial Multidrug Resistance.

Authors:  A J Heffernan; F B Sime; J Lipman; J A Roberts
Journal:  Drugs       Date:  2018-04       Impact factor: 9.546

6.  Emergence of linezolid-resistant Staphylococcus aureus after prolonged treatment of cystic fibrosis patients in Cleveland, Ohio.

Authors:  Andrea Endimiani; Martha Blackford; Elliot C Dasenbrook; Michael D Reed; Saralee Bajaksouszian; Andrea M Hujer; Susan D Rudin; Kristine M Hujer; Vincent Perreten; Louis B Rice; Michael R Jacobs; Michael W Konstan; Robert A Bonomo
Journal:  Antimicrob Agents Chemother       Date:  2011-01-24       Impact factor: 5.191

7.  In vitro resistance studies with bacteria that exhibit low mutation frequencies: prediction of "antimutant" linezolid concentrations using a mixed inoculum containing both susceptible and resistant Staphylococcus aureus.

Authors:  Alexander A Firsov; Maria V Golikova; Elena N Strukova; Yury A Portnoy; Andrey V Romanov; Mikhail V Edelstein; Stephen H Zinner
Journal:  Antimicrob Agents Chemother       Date:  2014-12-01       Impact factor: 5.191

8.  Pharmacokinetics of linezolid in septic patients with and without extended dialysis.

Authors:  Stefanie Swoboda; Michael C Ober; Christoph Lichtenstern; Soundos Saleh; Vedat Schwenger; Hans-Günther Sonntag; Walter Emil Haefeli; Georg Hempel; Torsten Hoppe-Tichy; Markus A Weigand
Journal:  Eur J Clin Pharmacol       Date:  2009-12-16       Impact factor: 2.953

9.  Use of an in vitro pharmacodynamic model to derive a linezolid regimen that optimizes bacterial kill and prevents emergence of resistance in Bacillus anthracis.

Authors:  A Louie; H S Heine; K Kim; D L Brown; B VanScoy; W Liu; M Kinzig-Schippers; F Sörgel; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2008-05-05       Impact factor: 5.191

10.  Pharmacokinetics and pharmacodynamics of nemonoxacin against Streptococcus pneumoniae in an in vitro infection model.

Authors:  Wang Liang; Yuan-cheng Chen; Yu-ran Cao; Xiao-fang Liu; Jun Huang; Jia-li Hu; Miao Zhao; Qing-lan Guo; Shu-jing Zhang; Xiao-jie Wu; De-mei Zhu; Ying-yuan Zhang; Jing Zhang
Journal:  Antimicrob Agents Chemother       Date:  2013-04-15       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.